Glutamine was previously thought to be associated with obesity (Curtasu et al., 2019) and diabetes (Newgard et al., 2009), as higher levels of glutamine and related metabolites are part of the systematic response to higher blood glucose levels and act to stimulate insulin secretion to lower blood glucose levels (Newsholme et al., 2005). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.